<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38754">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601885</url>
  </required_header>
  <id_info>
    <org_study_id>M14-173</org_study_id>
    <nct_id>NCT02601885</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis</brief_title>
  <official_title>An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the safety, tolerability, pharmacokinetics (PK) and
      immunogenicity of ABT-555 in participants with relapsing forms of multiple sclerosis (RFMS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and percentage of participants reporting adverse events</measure>
    <time_frame>Throughout study from Day 1 to Day 176</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of ABT-555</measure>
    <time_frame>Day 1 to Day 176</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum observed plasma concentration (Tmax) of ABT-555</measure>
    <time_frame>Day 1 to Day 176</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration curve (AUC) of ABT-555</measure>
    <time_frame>Day 1 to Day 176</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of anti-drug antibody (ADA) titers of ABT-555</measure>
    <time_frame>Day 1 to Day 176</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who experience relapse and disability progression</measure>
    <time_frame>Throughout the study to Day 176</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new, newly-enlarging T2 hyperintense lesions</measure>
    <time_frame>Throughout study from Day 0 to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion volume of new, newly enlarging T2 hyperintense lesions</measure>
    <time_frame>Throughout study from Day 0 to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of new Gadolinium-enhancing T1 lesions</measure>
    <time_frame>Throughout study from Day 0 to Day 113</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple doses of ABT-555 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple doses of ABT-555 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple doses of ABT-555 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-555</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently receiving one of the following MS medications for at least 3 months:
             beta-interferon (any formulation including the pegylated form), glatiramer acetate
             (Copaxone®, others), teriflunomide (Aubagio®), fingolimod (Gilenya®), or dimethyl
             fumarate (Tecfidera®); OR

          -  Has not been treated with an MS immunotherapy for the past 6 months (12 months if
             they previously received cyclophosphamide or alemtuzumab); OR

          -  Treatment naïve with established MS diagnosis per criteria by a neurologist.

          -  Diagnosis of relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS)
             according to revised McDonald criteria

          -  Baseline Expanded Disability Status Scale (EDSS) between 0 and 6.0, inclusive.

          -  Brain MRI scan at Screening that did not show evidence of overt vascular lesions,
             masses, mass effect or other abnormalities other than those compatible with MS, which
             would preclude the participant from undergoing a lumbar puncture/spinal tap for CSF
             collection

        Exclusion Criteria:

          -  Diagnosis of primary progressive MS.

          -  Anticipated maintenance immunomodulator change, either agent or dose

          -  An MS relapse that occurred within the 30 days prior to randomization AND/OR the
             participant has not stabilized from a previous relapse prior to randomization

          -  Participants for whom MRI is contraindicated

          -  Participants who have claustrophobia that cannot be medically managed or are unable
             to lie still for 1 hour or more for the imaging procedures

          -  Findings on brain MRI scan indicating any clinically significant brain abnormality
             other than MS

          -  Contraindication for lumbar puncture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Ziemann, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie_Call Center</last_name>
    <phone>847-283-8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>WCCT Global, LLC /ID# 145837</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IMMUNOe Research Centers /ID# 141561</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Compass Research LLC /ID# 141560</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Parexel International-EPCU Baltimore /ID# 141563</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 5, 2017</lastchanged_date>
  <firstreceived_date>November 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Secondary progressive</keyword>
  <keyword>Relapsing-remitting</keyword>
  <keyword>Relapsing forms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
